Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19457843 | 0.81 | CDK2 (0.31) | CDK2 | |
| SCHEMBL620246 | 0.76 | CSNK1A1 (0.41) | CDK2SCN2A | |
| SCHEMBL31511514 | 0.76 | CSNK1A1 (0.41) | CDK2SCN2A | |
| SCHEMBL20977360 | 0.73 | ALDH1A1 (0.33) | CDK2 | |
| SCHEMBL8257576 | 0.69 | — | — | |
| SCHEMBL24886370 | 0.69 | MAPKAPK2 (0.39) | CDK2 | |
| SCHEMBL19710551 | 0.69 | PLAU (0.34) | — | |
| SCHEMBL14611549 | 0.69 | — | — | |
| SCHEMBL31605046 | 0.68 | — | — | |
| SCHEMBL31526504 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724070-A2 | WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12528806-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12421233-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12344609-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250206738-A1 | WRN INHIBITORS | NIMBUS DISCOVERY, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2025137599-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250171440-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250171441-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250171442-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250034136-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2024254511-A2 | WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3990443-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206738-A1 | WRN INHIBITORS | WRN, BLM, RECQL | CDK2 650/4885SCN2A 3857/4885 |
| US-20250171440-A1 | WRN INHIBITORS | WRN, BLM, RECQL | CDK2 427/4885SCN2A 3244/4885 |
| US-20250171441-A1 | WRN INHIBITORS | WRN, BLM, RECQL | CDK2 650/4885SCN2A 3857/4885 |
| US-12421233-B2 | WRN inhibitors | WRN, BLM, RECQL | CDK2 650/4885SCN2A 3857/4885 |
| US-12344609-B2 | WRN inhibitors | WRN, BLM, RECQL | CDK2 427/4885SCN2A 3244/4885 |
| US-20250034136-A1 | WRN INHIBITORS | WRN, BLM, RECQL | CDK2 650/4885SCN2A 3857/4885 |
| US-20250171442-A1 | WRN INHIBITORS | WRN, BLM, RECQL | CDK2 704/4885SCN2A 3853/4885 |
| US-12528806-B2 | WRN inhibitors | WRN, RECQL, BLM | CDK2 1294/4885SCN2A 1957/4885 |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | PDGFRB, PDGFRA, FGFR1 | CDK2 116/4885SCN2A 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.